HC Wainwright restated their buy rating on shares of Chimerix (NASDAQ:CMRX - Free Report) in a research report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $11.00 target price on the biopharmaceutical company's stock.
Several other analysts have also issued reports on the stock. StockNews.com upgraded shares of Chimerix from a "sell" rating to a "hold" rating in a research report on Wednesday, August 21st. Wedbush reiterated an "outperform" rating and issued a $6.00 price target on shares of Chimerix in a research note on Tuesday.
View Our Latest Stock Analysis on CMRX
Chimerix Stock Up 8.0 %
Shares of CMRX traded up $0.22 during trading hours on Wednesday, hitting $2.98. 9,916,837 shares of the company were exchanged, compared to its average volume of 1,226,708. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $3.39. The company has a market cap of $268.02 million, a price-to-earnings ratio of -3.15 and a beta of 1.02. The firm's fifty day moving average is $0.94 and its 200 day moving average is $0.91.
Institutional Trading of Chimerix
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Valeo Financial Advisors LLC lifted its stake in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 69,505 shares during the last quarter. Marshall Wace LLP bought a new position in Chimerix in the second quarter valued at about $137,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. Institutional investors own 45.42% of the company's stock.
About Chimerix
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
See Also
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
